Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 20/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12416494 | 0.94 | GHSR (0.85) | GHSR | |
| SCHEMBL8272346 | 0.94 | GHSR (0.85) | GHSR | |
| SCHEMBL12135983 | 0.92 | GHSR (0.85) | GHSR | |
| SCHEMBL2759179 | 0.92 | GHSR (0.85) | GHSR | |
| SCHEMBL12135922 | 0.92 | GHSR (0.85) | GHSR | |
| SCHEMBL8272345 | 0.91 | GHSR (1.00) | GHSR | |
| SCHEMBL8272396 | 0.91 | GHSR (1.00) | GHSR | |
| SCHEMBL2759178 | 0.87 | GHSR (0.86) | GHSR | |
| SCHEMBL12134632 | 0.86 | GHSR (1.00) | GHSR | |
| SCHEMBL14629163 | 0.86 | GHSR (0.84) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180110824-A1 | Macrocyclic Modulators of the Ghrelin Receptor | OCERA THERAPEUTICS, INC. | 2018-04-26 | — | — | US | disclosed |
| US-9493505-B2 | Macrocyclic modulators of the ghrelin receptor | OCERA THERAPEUTICS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150148290-A1 | Macrocyclic Modulators of the Ghrelin Receptor | MALLINCKRODT LLC | 2015-05-28 | — | — | US | disclosed |
| US-8921521-B2 | Macrocyclic modulators of the Ghrelin receptor | OCERA THERAPEUTICS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20130211045-A1 | MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | TRANZYME PHARMA INC. (CA) | 2013-08-15 | — | — | US | disclosed |
| US-8349887-B2 | Methods of treating cachexia with macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. (CA) | 2013-01-08 | — | — | US | disclosed |
| US-20120071412-A1 | METHODS OF USING MACROCYCLIC AGONISTS OF THE GHRELIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL MOTILITY DISORDERS | FRASER GRAEME L (BE) | 2012-03-22 | — | — | US | disclosed |
| US-8088733-B2 | Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders | TRANZYME PHARMA INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20110288163-A1 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | MALLINCKRODT US HOLDINGS LLC | 2011-11-24 | — | — | US | disclosed |
| US-RE42624-E1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. (CA) | 2011-08-16 | — | — | US | disclosed |
| US-7491695-B2 | Therapy for endocrime disorders; gastrointestinal disorders; cardiovascular disorders; obesity; central nervous system disorders; antiproliferative agents ; using growth hormone secretagogue receptor | TRANZYME PHARMA INC. (CA) | 2009-02-17 | — | — | US | disclosed |
| US-7491695-B2 | Therapy for endocrime disorders; gastrointestinal disorders; cardiovascular disorders; obesity; central nervous system disorders; antiproliferative agents ; using growth hormone secretagogue receptor | TRANZYME PHARMA INC. (CA) | 2009-02-17 | — | — | US | disclosed |
| US-7476653-B2 | Using growth hormone secretagague receptors; endocrime disorders; gastrointestinal disorders; cardiovascular disorders; central nervous system disorders; antiproliferative agents; antiinflammatory agents | TRANZYME PHARMA, INC. (CA) | 2009-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288163-A1 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | GHSR, GHRHR, GIPR | GHSR 1/4885 |
| US-20180110824-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | GHSR 1/4885 |
| US-20150148290-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | GHSR 1/4885 |
| US-20130211045-A1 | MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | GHSR, GIPR, GHRHR | GHSR 1/4885 |
| US-20120071412-A1 | METHODS OF USING MACROCYCLIC AGONISTS OF THE GHRELIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL MOTILITY DISORDERS | GHSR, GIPR, GHRHR | GHSR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.